Natural chemical drug production research institute
Production and research company of organ on-chip monitoring system
and antioxidant product (antioxidant dressing, macular degeneration drug, cardiovascular drug)
|Division||Organ On-Chip Monitoring System||Zeaxanthin||9-cis β-carotene|
|Product||Organ On-Chip Monitoring System||Pharmaceutical Raw Material for Macular Degeneration Treatment||Atherosclerosis Treatment|
|Characteristic||Produced in an environment similar to an actual arterial blood vessel, cultured human cells on a chip, and tested for toxicity and effect reactions of drugs through blood supply.||Zeaxanthin is the material of Highly purified microalgae
The Highest Value among the purified products(Lutein, Meso-Zeaxanthin)
|9-cis β-Carotene is discomposed into two substances, 9-cis Retinoid which break down fat cells in the blood and All-Trans-Retinoid that neutralize blood clotting by acting on the thrombus. Both of them have efficacy in the treatment of atherosclerosis.|
|Market Value||The market size of the in vitro diagnostics market is expected to be about USD 218.2 billion in 2025, and in addition, we will enter the market through drug screening services at domestic and overseas hospitals.||The market size of the macular degeneration is about USD 4billion in 2014 and CAGR 7.8%. It is estimated to reach USD 8billion by 2023.||Cardio-cerebrovascular disease is #1 cause of death in the world
The global Atherosclerosis therapeutics market stood at $35 billion in 2012 and will grow at $45 billion by 2022.
|Business Value||Expected to sell equipment and services to the pathology laboratory of pharmaceutical research institutes, universities, national and public hospitals, and clinical research institutes hospitals.||The macular degeneration drugs in Korea are all import-dependent and most of the treatments contain about 25% Zeaxanthin.
We are in business agreement with Pharmaceutical Company ‘H’(No.1 Korea company in prescription medicine of Eye Drop domestic technology).
|We are the only company related to Atherosclerosis therapeutics in Korea Bio-Venture and hold the patent about 9-cis β-Carotene purification process.|